Komori
Financial results presentation4507Shionogi & Co.,Ltd.Pharmaceuticals

Supplementary Financial Results Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending March 22027

From April to September 2026, sales revenue and operating profit substantially exceeded the same period of the previous year, mainly due to the consolidation of Torii Pharmaceutical, the transfer of the edaravone business, growth in overseas subsidiaries and exports, and an increase in royalty income. However, growth in profit before tax was limited by a decrease in financial income and an increase in financial expenses.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1374
¥100 million (year-on-year change in sales revenue)
Wording
Definitive
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥3,504 100 million+64.5%
Operating profit¥1,152 100 million+55.8%
Net income¥1,195 100 million +44.0%attributable to owners of the parent
Selling, general and administrative expenses¥905 100 million
Operating profit margin
Rate32.9 %
Year-on-year change (points)-1.8 %
Results for the three months of the current quarter
Revenue
April-June
¥1,633 100 million+63.7%
July-September
¥1,871 100 million+65.3%
Operating profit
April-June
¥513 100 million+46.1%
July-September
¥640 100 million+64.6%
Profit attributable to owners of the parent
April-June
¥818 100 million+107.9%
July-September
¥377 100 million-13.5%
Full-year earnings forecast
Revenue
¥7,200 100 million
Gross profit
¥5,950 100 million
Selling, general and administrative expenses
¥1,935 100 million
R&D Expenses
¥1,400 100 million
Amortization of Intangible Assets Related to Products
¥715 100 million
Operating profit
¥2,300 100 million
Pretax profit
¥2,205 100 million
Profit attributable to owners of the parent
¥2,125 100 million
Capital expenditures
¥358 100 million
Depreciation and amortization
¥955 100 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Consolidated
Revenue48.7
Gross profit48.2
Selling, general and administrative expenses46.7
R&D Expenses48.2
Amortization of Intangible Assets Related to Products42.2
Operating profit50.1
Financial income84.1
Pretax profit48.6
Profit attributable to owners of the parent56.3
Revenue by Business
Prescription Medicines in Japan43.2
Overseas Subsidiaries/Exports49.7
Contract development and manufacturing50.1
Over-the-counter medicines44.9
Royalty income51.1
Other46.7
Capital expenditures25.6
Depreciation and amortization43.8
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue
Prescription Medicines in Japan375
Overseas Subsidiaries/Exports644
Royalty income361
Cost of sales
Increase due to the consolidation of Torii Pharmaceutical and the transfer of the edaravone business339
Selling, general and administrative expenses
Increase in sales-related expenses in the U.S. business and in connection with the consolidation of Torii Pharmaceutical371
R&D Expenses
Increase due to the pharmaceutical business of JT and the consolidation of Torii Pharmaceutical150
Amortization of Intangible Assets Related to Products
Increase due to the pharmaceutical business of JT and the transfer of the edaravone business291
Other Income
Increase due to ViiV becoming an equity-method affiliate, impairment losses on assets subject to the share transfer agreement for a Chinese group company, and other factors249
Financial income
Decrease due to ViiV becoming an equity-method affiliate-193
Financial Expenses
Increase in interest expense and foreign exchange losses123
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
Dollar159
Pound213.4
Euro184.4
New initiatives
  • In April 2026, the edaravone business was transferred from 田辺ファーマ株式会社
  • Progress in the approval and filing of products under development (cefiderocol, S-268024, ensitrelvir, tapinarof, etc.)
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥1,746 100 million+103.3%
  • Basic earnings per share¥140.47+44.0%
  • Diluted Earnings per Share¥140.43+44.0%
  • ROE7 %+1.1%
  • ROA4.1 %-2.1%
  • Operating Margin on Revenue32.9 %-1.8%
  • Equity ratio attributable to owners of the parent66.1 %-0.7%
Segment results
Prescription Medicines in Japan
Sales
¥743 100 million
Year on year against the same period last year+101.7%
Overseas Subsidiaries/Exports
Sales
¥950 100 million
Year on year against the same period last year+210.2%
Contract development and manufacturing
Sales
¥66 100 million
Year on year against the same period last year-6.7%
Over-the-counter medicines
Sales
¥78 100 million
Year on year against the same period last year-1.0%
Royalty income
Sales
¥1,654 100 million
Year on year against the same period last year+27.9%
Other
Sales
¥12 100 million
Year on year against the same period last year+2.4%
Number of employees
Number of Employees
End of June 20266,453
End-September 20266,502
Change during the period49 people
Capital expenditures
¥92 100 million
Payout ratio
FY2025 actual results28.9 %
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending March 2027
Net Sales¥3,504 100 million (YoY +64.5%)
Operating profit¥1,152 100 million (YoY +55.8%)
Net income¥1,195 100 million (attributable to owners of the parent) (YoY +44.0%)
Operating profit marginRate 32.9 % / Year-on-year change (points) -1.8 %
Selling, general and administrative expenses¥905 100 million
Results for the three months of the current quarterRevenue April-June ¥1,633 100 million (YoY +63.7%) / July-September ¥1,871 100 million (YoY +65.3%) / Operating profit April-June ¥513 100 million (YoY +46.1%) / July-September ¥640 100 million (YoY +64.6%) / Profit attributable to owners of the parent April-June ¥818 100 million (YoY +107.9%) / July-September ¥377 100 million (YoY -13.5%)
Full-year earnings forecastRevenue ¥7,200 100 million / Gross profit ¥5,950 100 million / Selling, general and administrative expenses ¥1,935 100 million / R&D Expenses ¥1,400 100 million / Amortization of Intangible Assets Related to Products ¥715 100 million / Operating profit ¥2,300 100 million / Pretax profit ¥2,205 100 million / Profit attributable to owners of the parent ¥2,125 100 million / Capital expenditures ¥358 100 million / Depreciation and amortization ¥955 100 million
Progress against full-year forecastConsolidated Revenue 48.7 / Gross profit 48.2 / Selling, general and administrative expenses 46.7 / R&D Expenses 48.2 / Amortization of Intangible Assets Related to Products 42.2 / Operating profit 50.1 / Financial income 84.1 / Pretax profit 48.6 / Profit attributable to owners of the parent 56.3 / Revenue by Business Prescription Medicines in Japan 43.2 / Overseas Subsidiaries/Exports 49.7 / Contract development and manufacturing 50.1 / Over-the-counter medicines 44.9 / Royalty income 51.1 / Other 46.7 / Capital expenditures 25.6 / Depreciation and amortization 43.8
Segment resultsPrescription Medicines in Japan Sales ¥743 100 million / yoy_pct 101.7 / Overseas Subsidiaries/Exports Sales ¥950 100 million / yoy_pct 210.2 / Contract development and manufacturing Sales ¥66 100 million / yoy_pct -6.7 / Over-the-counter medicines Sales ¥78 100 million / yoy_pct -1 / Royalty income Sales ¥1,654 100 million / yoy_pct 27.9 / Other Sales ¥12 100 million / yoy_pct 2.4
Breakdown of Factors Affecting the ChangeRevenue Prescription Medicines in Japan 375 / Overseas Subsidiaries/Exports 644 / Royalty income 361 / Cost of sales Increase due to the consolidation of Torii Pharmaceutical and the transfer of the edaravone business 339 / Selling, general and administrative expenses Increase in sales-related expenses in the U.S. business and in connection with the consolidation of Torii Pharmaceutical 371 / R&D Expenses Increase due to the pharmaceutical business of JT and the consolidation of Torii Pharmaceutical 150 / Amortization of Intangible Assets Related to Products Increase due to the pharmaceutical business of JT and the transfer of the edaravone business 291 / Other Income Increase due to ViiV becoming an equity-method affiliate, impairment losses on assets subject to the share transfer agreement for a Chinese group company, and other factors 249 / Financial income Decrease due to ViiV becoming an equity-method affiliate -193 / Financial Expenses Increase in interest expense and foreign exchange losses 123
Key KPIsEBITDA ¥1,746 100 million (YoY +103.3%), Basic earnings per share ¥140.47 (YoY +44.0%), Diluted Earnings per Share ¥140.43 (YoY +44.0%), ROE 7 % (YoY +1.1%), ROA 4.1 % (YoY -2.1%), Operating Margin on Revenue 32.9 % (YoY -1.8%), Equity ratio attributable to owners of the parent 66.1 % (YoY -0.7%)
Number of employeesNumber of Employees End of June 2026 6,453 / End-September 2026 6,502 / Change during the period 49 people
Assumptions Underlying the Business OutlookExchange rate Dollar 159 / Pound 213.4 / Euro 184.4
Payout ratio28.9 %
Capital expenditures¥92 100 million
New initiativesIn April 2026, the edaravone business was transferred from 田辺ファーマ株式会社, Progress in the approval and filing of products under development (cefiderocol, S-268024, ensitrelvir, tapinarof, etc.)
Items this document does not state (13)
Ordinary incomeGross Profit MarginSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Sales revenue increased by ¥37.5 billion from domestic prescription pharmaceuticals, ¥64.4 billion from overseas subsidiaries and exports, and ¥36.1 billion from royalty income. While gross profit increased, operating profit was affected by higher selling-related expenses for the US business, the consolidation of Torii Pharmaceutical, and higher costs associated with the transfer of the JT pharmaceutical business and the edaravone business. Profit before tax was affected by a decrease in financial income related to the application of the equity method to ViiV's interest and increases in interest expense and foreign exchange losses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending March 22027 | Shionogi & Co.,Ltd. (4507) timely disclosure | Komori